Clinical Trial Update: A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

A Phase 2 open-label study evaluating BA3021 in patients with recurrent or metastatic head and neck squamous cell carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• BA3021

Snippet

Sponsor: BioAtla, Inc. | Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Phase 2 | Status: COMPLETED